Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622401 · ClinicalTrials.gov registry record · Phase 1
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00622401: Clinical Trial Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00622401 is a Phase 1 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00622401, a Phase 1 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12 may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-12 when given together with vaccine therapy and to see how well they work in treating women with stage IV breast cancer.
Primary Outcome
Using CTCAE version 3, adverse events associated with the intervention were captured throughout the treatment portion of the study. All adverse events were then compiled and the number of patients who experienced these adverse events was recorded.
Interventions
- BIOLOGICAL Dendritic Cell/Tumor Fusion Vaccine
- DRUG Interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Why NCT00622401 stopped before completion
NCT00622401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Dendritic Cell/Tumor Fusion Vaccine is the first listed.
NCT00622401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00622401 about?
NCT00622401 is a clinical study titled "Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12". The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor c...
What is the current status of trial NCT00622401?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00622401?
The interventions under investigation include: Dendritic Cell/Tumor Fusion Vaccine (BIOLOGICAL), Interleukin-12 (DRUG).
Who is sponsoring clinical trial NCT00622401?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00622401's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia